Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Income from Continuing Operations (2016 - 2025)

Spyre Therapeutics' Income from Continuing Operations history spans 11 years, with the latest figure at 62530000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 11.07% year-over-year to 62530000.0; the TTM value through Dec 2025 reached 155203000.0, up 25.39%, while the annual FY2025 figure was 155203000.0, 25.39% up from the prior year.
  • Income from Continuing Operations reached 62530000.0 in Q4 2025 per SYRE's latest filing, down from 11183000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 6830000.0 in Q2 2021 to a low of 217081000.0 in Q2 2023.
  • Average Income from Continuing Operations over 5 years is 42579800.0, with a median of 30576500.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: plummeted 872.45% in 2023, then soared 83.8% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 20446000.0 in 2021, then increased by 7.94% to 18822000.0 in 2022, then crashed by 235.67% to 63180000.0 in 2023, then grew by 10.9% to 56296000.0 in 2024, then dropped by 11.07% to 62530000.0 in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Income from Continuing Operations are 62530000.0 (Q4 2025), 11183000.0 (Q3 2025), and 36717000.0 (Q2 2025).